Market Newsdesk

Editorial Commentary — Commercial Space Series

SpaceX
‘
s public listing cast Starlink Mobile as a future wireless challenger. AST SpaceMobile (NASDAQ: ASTS) is the most prominent publicly traded company pursuing the same direct-to-device satellite-broadband market.

Key Takeaways

• The SpaceX IPO prospectus framed Starlink Mobile as a direct-to-smartphone service intended to compete with terrestrial mobile networks — spotlighting a market that public investors cannot access through SpaceX alone.
• AST SpaceMobile (NASDAQ: ASTS) is the most prominent listed company building a direct-to-device satellite-broadband network, connecting ordinary, unmodified smartphones from space.
• AST has reported securing over US$1.2 billion in aggregate contracted revenue commitments from partners, and is targeting 45 to 60 satellites in orbit by the end of 2026.
• Other listed satellite-connectivity names include Globalstar (NASDAQ: GSAT) and Viasat (NASDAQ: VSAT) — each distinct, and neither a proxy for the other.

The IPO That Made Satellite-to-Phone a Headline

VANCOUVER, BC, June 27, 2026 /PRNewswire/ — Equity Insider Market Commentary, When Space Exploration Technologies Corp. (SpaceX) filed to go public on the Nasdaq under the proposed ticker SPCX, the prospectus did more than reveal the financials of the world’s most valuable private company. It laid out, in detail, how SpaceX intends to turn its Starlink constellation into a wireless competitor — casting Starlink Mobile as a direct-to-smartphone service designed to perform “on par with terrestrial mobile networks,” with next-generation satellites slated to expand the offering beyond messaging toward full broadband and IoT connectivity. Get our free Orbital Economy Signal Brief for plain-English intelligence on the commercial-space sector, delivered as it moves.

That framing turned a once-niche idea — connecting an ordinary phone directly to a satellite, with no special hardware — into a front-page investment theme. But there is a catch for public investors: SpaceX’s satellite-to-phone business is bundled inside an enormous company spanning launch, Starlink broadband, and an artificial-intelligence unit. For those seeking a focused, public-market way to play the direct-to-device race specifically, the most prominent name is not SpaceX at all. It is AST SpaceMobile.

AST SpaceMobile: The Public Pure-Play on Phones-From-Space

AST SpaceMobile (Nasdaq: ASTS), based in Midland, Texas, is building what it calls a space-based cellular broadband network designed to connect everyday, unmodified smartphones directly to its satellites — aiming to eliminate mobile “dead zones” worldwide. Where Starlink began as a fixed-broadband service using dedicated terminals, AST’s entire thesis is the direct-to-device market that SpaceX’s IPO filing has now thrust into the spotlight. That makes the two natural — if vastly differently sized — competitors in the same emerging category.

The company has been building both its constellation and its commercial foundation. AST reported full-year 2025 revenue of about US$70.9 million, driven by mobile-network-operator partners and the U.S. government, and said it had secured over US$1.2 billion in aggregate contracted revenue commitments from partners — a figure that speaks to the scale of carrier interest. It has also reported completing the in-orbit unfolding of BlueBird 6, which it described as the largest commercial communications array ever deployed in low Earth orbit, and has laid out a launch cadence intended to reach 45 to 60 satellites in orbit by the end of 2026.

The risk profile is equally clear, and worth stating plainly: AST is a capital-intensive, still-largely-pre-revenue business whose value depends on executing a demanding manufacturing-and-launch campaign on schedule. A successful deployment validates the model; a stumble in cadence or array deployment would do the opposite. This is a build-it-first business, and the build is far from finished.

How AST and SpaceX Actually Differ

It would be a mistake to treat AST as a miniature Starlink. The two take different technical and commercial approaches: AST partners with terrestrial mobile-network operators to extend their existing networks from space, positioning itself as a complement that carriers integrate, rather than a stand-alone consumer ISP. SpaceX, by contrast, has the advantage of owning its own launch vehicles — it flies Starlink satellites on its own Falcon 9 and Starship rockets — plus enormous scale and a head start in subscribers. AST’s counter is focus and carrier alignment: it is building specifically for the direct-to-device use case in partnership with the incumbents whose customers it would serve. Which model wins, or whether both coexist, is exactly the open question the SpaceX IPO has made unavoidable. Tracking how this sector is being repriced in real time? Join the free Orbital Economy Signal Brief to follow the shifts as they happen.

The Wider Satellite-Connectivity Field

Beyond AST, a couple of listed satellite-connectivity companies help frame the landscape — each with a distinct model and risk profile, and neither a proxy for the other. Globalstar (Nasdaq: GSAT) provides mobile satellite services and wholesale capacity, reporting first-quarter 2026 revenue of about US$70.1 million, up 17% year-over-year, and has been a long-running infrastructure partner in the satellite-to-phone space. Viasat (Nasdaq: VSAT) anchors the broadband-and-connectivity end as a diversified satellite-communications operator serving aviation, government, and consumer markets. Together with AST, these names show that “satellite connectivity” spans several business models — wholesale capacity and diversified broadband — all being re-rated as the direct-to-device opportunity SpaceX highlighted draws fresh capital and attention. Each, however, will live or die on its own constellation, balance sheet, and execution.

A Note on the Broader Space Trade

One smaller name investors scanning the sector may note is Starfighters Space, Inc. (NYSE American: FJET), mentioned here for context only and not as a recommendation. The company has publicly described operating what it calls the world’s only commercial fleet of flight-ready Mach 2+ supersonic F-104 aircraft from NASA’s Kennedy Space Center, and in May 2026 it announced a US$17.5 million strategic equity investment led by institutional investors, with proceeds earmarked to support operational expansion and continued advancement of its STARLAUNCH platform. These are the company’s own announced figures; readers should verify them in its filings.

The Bottom Line

The SpaceX IPO did more than reveal Starlink’s economics — it confirmed that connecting ordinary phones directly to satellites is a market the most sophisticated player in space intends to pursue aggressively. For public investors, that validation lands not on SpaceX’s sprawling franchise but on the focused names building in the same direction. AST SpaceMobile is the most prominent of them, with carrier commitments and an ambitious deployment plan — and the considerable execution risk that comes with building a constellation from scratch. The question the IPO sharpened is no longer whether satellite-to-phone is real, but who builds the winning network. The answer will come from orbit, on a schedule, over the next several years. To keep a closer eye on the launch, satellite, lunar, and space-data economy as it develops, sign up for the free Orbital Economy Signal Brief.

SIGNAL OVER NOISE

Signal over noise. Space, satellite-connectivity, and telecom headlines move fast — and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.

CONTACT

Equity Insider
[email protected]

SOURCES

[1] Space Exploration Technologies Corp. (SpaceX), Form S-1 registration statement and Starlink Mobile disclosures (proposed Nasdaq symbol SPCX), May–June 2026, sec.gov; contemporaneous news reporting.
[2] AST SpaceMobile, Inc. (Nasdaq: ASTS), Q4 and full-year 2025 results and business update, March 2, 2026.
[3] Globalstar, Inc. (Nasdaq: GSAT), Q1 2026 financial results, May 7, 2026.
[4] Viasat, Inc. (Nasdaq: VSAT), corporate disclosures, 2026.
[5] Starfighters Space, Inc. (NYSE American: FJET), company press releases ($17.5 million strategic investment; STARLAUNCH; Kennedy Space Center operations), 2026.

DISCLAIMER

IMPORTANT — PLEASE READ: This article is editorial commentary and was NOT paid for, requested, commissioned, reviewed, or approved by any of the companies named in it, nor by Creative Direct Marketing Group (“CDMG”). No company mentioned in this article paid for or had any involvement in its preparation or publication. The disclosures that follow are provided in the interest of full transparency regarding our broader business relationships, even though they do not apply to this specific article.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This publication is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is owned and operated by Market IQ Media Group Limited, a company incorporated under the laws of Ireland (“MIQL”). As part of its ongoing business, MIQL has been paid fees by CDMG for advertising and digital media for Starfighters Space, Inc. (NYSE American: FJET) in connection with separate, paid campaigns; those paid materials are distinct from this article, which is unpaid editorial. This relationship constitutes a potential conflict of interest as to our ability to remain objective in our commentary regarding Starfighters Space, Inc., and readers are strongly encouraged not to use this publication as the basis for any investment decision. MIQL and its owner/operators do not own shares of Starfighters Space, Inc. or of any other company named in this article in connection with this piece, but reserve the right to buy and sell securities of any company mentioned at any time without further notice. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements concerning the companies referenced and the commercial-space sector, including statements regarding the proposed initial public offering of Space Exploration Technologies Corp. (“SpaceX”) and its reported terms, which are based on third-party reporting and SpaceX’s own filings and remain subject to change until and unless finalized; product development, launch and mission timelines; contract awards and backlog; and broader market conditions. Forward-looking statements are not guarantees of future results and are subject to risks and uncertainties — including execution, regulatory, financing, competitive and macroeconomic risks — that could cause actual results to differ materially, as detailed in each referenced company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. References to SpaceX are for thematic and contextual purposes only; SpaceX is a separate company with no affiliation to the publisher, and nothing herein is an offer to buy or sell, or a solicitation of any offer to buy or sell, securities of SpaceX or any other company. Figures attributed to named companies are drawn from those companies’ public disclosures. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made; the publisher undertakes no obligation to update or revise them except as required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-spacex-ipo-put-a-spotlight-on-starlink–and-on-the-one-public-company-building-a-rival-direct-to-phone-network-302812572.html

HONG KONG, June 27, 2026 /PRNewswire/ — Waton Financial Limited (NASDAQ: WTF) today announced the release of MoTA Alpha, a major upgrade to its flagship AI-powered investment platform. First unveiled in closed beta in May 2026, MoTA (Manager of Trading Agents) now introduces the Agent Talents Market, a creator ecosystem for third-party AI trading agents, alongside a redesigned multi-agent collaboration workflow and a fully overhauled user experience. The Alpha release represents more than a product milestone — it signals Waton’s decisive transition from a securities brokerage and SaaS provider into an AI-native financial technology company.

MoTA Alpha: What’s New

MoTA Alpha builds on the beta’s foundation as an AI-native investment team workbench — a platform that enables professional investors and portfolio managers to assemble, manage, and supervise teams of specialized AI agents across research, analysis, risk, and execution functions within a structured, auditable workflow, with mandatory human review and final sign-off at every stage.

Three headline upgrades define this release:

1. Agent Talents Market
   An open marketplace where third-party developers can create, publish, and rank AI trading agents. Users subscribe to or deploy agents built by independent creators, with all agents running on Waton’s infrastructure. Agent’s internal logic remains under creator control; Waton provides the platform layer and execution environment.

2. Enhanced Multi-Agent Collaboration
   A rebuilt task orchestration layer that improves inter-agent communication, role assignment, and decision audit trails. The result is a workflow that mirrors the dynamics of a real investment team — each agent operates within its mandate, escalates to human supervisors where required, and maintains a complete, reviewable log.

3. Redesigned Interface
   A significantly improved user experience that preserves MoTA’s distinctive 8-bit pixel-art visual identity — a deliberate departure from the blue-and-white minimalism that dominates fintech — while increasing information density and operational speed for professional workflows.

The Strategic Pivot

MoTA Alpha represents the clearest demonstration yet of Waton’s evolution from a financial infrastructure provider into an AI-native product company.

Since its NASDAQ listing in April 2025, Waton has positioned itself as the world’s first publicly traded AI agent holding company. Yet its revenue base has remained rooted in traditional securities brokerage and Broker Cloud SaaS solutions serving institutional clients in Hong Kong. MoTA Alpha changes that equation: AI is no longer a narrative layer on top of an existing brokerage business — it is now a tangible, independently monetizable product line.

The company is structuring itself around a “brokerage infrastructure + AI application” dual-engine model. This is a meaningfully different profile from either pure-play online brokers or conventional fintech SaaS firms, positioning Waton closer to the emerging category of AI-native financial platforms.

Financial Foundation

According to Waton’s unaudited financial results for the first half of fiscal year 2026 (six months ended September 30, 2025), total revenues rose 106.3% year-on-year to $6.10 million, driven by a 223.1% increase in brokerage and commission income to $4.17 million. Cash and segregated cash stood at $29.88 million, with total assets of $68.98 million.

Notably, the company reported research and development expenses as a standalone line item for the first time ($0.39 million in H1 FY2026), alongside significant share-based compensation tied to AI product development. MoTA Alpha is the first scaled output of this R&D pipeline.

Management Commentary

“The Alpha release of MoTA marks Waton’s evolution from a financial technology services provider to an AI-era infrastructure and product company,” said Zhou Kai (Tony Zhou), Chairman and Chief Technology Officer of Waton Financial. “We are not building a chatbot for trading. We are building a platform where professional investors manage teams of AI agents — each with defined roles, clear accountability, and human oversight. The Agent Talents Market extends this further: MoTA transitions from a product into an ecosystem.”

Roadmap

Following the Alpha release, Waton expects to open MoTA to public beta testing in Q3 2026. The platform currently supports Hong Kong and U.S. equity markets, with digital asset coverage on the product roadmap. MoTA is available as a standalone application at m.mota.ai and integrates with Waton’s existing brokerage and TradingWTF infrastructure.

For investors tracking $WTF, MoTA Alpha serves as the first real test of whether the “AI agent holding company” thesis translates from corporate positioning into a durable commercial model.

Media Contact

https://www.wtf.us

https://www.mota.ai 

About Waton Financial Limited

Waton Financial Limited (NASDAQ: WTF) is the world’s first NASDAQ-listed AI agent holding company, dedicated to discovering, creating, investing in, and incubating AI agents that work for people. Its flagship product, MoTA (Manager of Trading Agent), enables professional investors to build, manage, and supervise teams of specialized AI agents within a structured, human-supervised workflow. The company also empowers global brokerage firms and financial institutions through Broker Cloud + SaaS + AI digital solutions. Learn more at https://wtf.us.

View original content:https://www.prnewswire.com/news-releases/waton-financial-launches-mota-alpha-marking-full-strategic-pivot-to-ai-native-finance-302812548.html

SOURCE Waton Financial Limited

NEW YORK, June 26, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

So what: If you purchased Veritone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Veritone class action, go to https://rosenlegal.com/cases/veritone-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Veritone inaccurately recorded and/or misclassified certain revenue and costs; (2) as a result, Veritone overstated its revenue, assets, accounts receivable, royalties and other comprehensive income; (3) Veritone maintained deficient internal controls over accounting and financial reporting; (4) as a result of the foregoing, Veritone would be forced to restate certain of its financial statements; and (5) as a result, defendants’ positive statements about Veritone’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Veritone class action, go to https://rosenlegal.com/cases/veritone-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veritone-deadline-veri-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-veritone-inc-securities-fraud-lawsuit-302812376.html

SOURCE THE ROSEN LAW FIRM, P. A.

NEW YORK and NEW ORLEANS, June 26, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. (“PicS” or the “Company”) (NasdaqGS: PICS) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company’s Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the “IPO”). This action is pending in the United States District Court for the Southern District of New York.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-pics/?prs=globe

PicS investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pics/?prs=globe to learn more.

CASE DETAILS: According to the Complaint, PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.’s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.’s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company’s business and financial results. 

The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.

WHAT TO DO? If you invested in PicS and suffered a loss during the relevant time frame, you have until August 4, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/pics-nv-notice-of-august-4-2026-application-deadline-for-class-action-lawsuit—contact-lewis-kahn-esq-at-kahn-swick–foti-llc-before-application-deadline-302812310.html

SOURCE ClaimsFiler

NEW YORK and NEW ORLEANS, June 26, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of GeneDx as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wgs/?prs=globe to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 3, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On May 4, 2026, the Company reported its financial results for the first quarter of fiscal year 2026, disclosing a drop in adjusted gross margin from 74% to 69%, that it had missed its revenue estimates for both its exome and genome lines, and lowered its guidance for full year revenue to $475 – $490 million, down from $540 – $550 million. The Company also disclosed a $31.2 million impairment loss attributable to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company, which the Company had touted as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.

On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.

The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/genedx-holdings-securities-fraud-class-action-result-of-acquisition-performance-misrepresentations-and-49-stock-decline—investors-may-contact-lewis-kahn-esq-at-kahn-swick–foti-llc-302812341.html

SOURCE Kahn Swick & Foti, LLC

TROY, Mich., June 26, 2026 /PRNewswire/ — The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Deckers Outdoor Corp. (NYSE: DECK) as its “Stock to Study” and Euronet Inc. (NYSE: EEFT) as its “Undervalued Stock” in the September 2026 issue for investors’ informational and educational use.

To help you along your way, BetterInvesting has a number of free resources including: https://www.betterinvesting.org/learn-about-investing/investor-education/college-saving/investment-strategies-in-saving-for-college

For a free lesson on 6 steps to successful investing, visit https://www.betterinvesting.org/learn-about-investing/investor-education/getting-started-with-stocks/6-steps-for-successful-stock-investing

To become a member and learn more about the principles of the National Association of Investors, visit https://www.betterinvesting.org/about-us/mission-method-of-stock-investing

Check the September 2026 issue of BetterInvesting Magazine for more details about the latest stocks. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Deckers Outdoor and Euronet by viewing their fundamental data and applying judgments.

Committee members are Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; and Anne Nichols, CFA.

As stated, the BetterInvesting committee’s Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC^®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization’s principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn and Facebook.

CONTACT: 877-275-6242

View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-deckers-outdoor-corpnyse-deck-and-euronet-inc-nyse-eeft-302812466.html

SOURCE NAIC-BetterInvesting

HOUSTON, June 26, 2026 /PRNewswire/ — Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the “Company” or “Decoy”), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the “PIPE”), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent’s fees and other financing expenses payable by the Company. The Company intends to use the net proceeds to advance its lead asset into clinical trials.

The PIPE consists of (i) $3.5 million of upfront gross proceeds at a purchase price of $5.91 per share from the sale of common stock (or pre-funded warrants in lieu thereof), (ii) a milestone-based Series A warrant with potential additional aggregate gross proceeds of approximately $3.5 million if fully exercised following both shareholder approval and the date of filing by the Company of a Clinical Trial Application with the applicable competent regulatory authority in the European Economic Area to commence a Phase 1 clinical trial, (iii) a milestone-based Series B warrant with potential additional aggregate gross proceeds of approximately $7.0 million if fully exercised following both shareholder approval and the Company’s receipt of formal written approval from the Medicines and Healthcare products Regulatory Agency to conduct a Phase 2a human challenge trial in the United Kingdom, and (iv) a milestone-based Series C warrant with potential additional aggregate gross proceeds of approximately $7.0 million if fully exercised following both shareholder approval and the Company’s public announcement of data from the Company’s positive Phase 2a human challenge trial conducted in the United Kingdom. The PIPE was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC, with each warrant having an exercise price equal to the deal price. The securities to be issued in the PIPE will be subject to applicable restrictions on transfer. The terms of the PIPE were determined through negotiations between the Company and the investors, based on the closing share price on the determination date.

The closing of the offering is expected to occur on or about June 29, 2026, subject to the satisfaction of customary closing conditions.

Curvature Securities LLC is acting as the sole placement agent in connection with the PIPE.

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of a registration rights agreement entered into with the investor, the Company agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) covering the resale of the shares of common stock issued or underlying pre-funded or common warrants issued to the institutional investor no later than 15 calendar days after the closing of the offering and to use commercially reasonable efforts to have the registration statement declared effective within 90 days following the closing of the offering in the event of a “full review” by the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP(3)ACT™ platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment. The Company’s lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “can,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on its business plans and risks related to Decoy’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP(3)ACT platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy’s actual results may vary materially from those expected or projected.

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-inc-announces-up-to-21-million-private-placement-financing-302812451.html

SOURCE Decoy Therapeutics, Inc

LISHUI, China, June 26, 2026 /PRNewswire/ — Farmmi, Inc. (NASDAQ: FAMI) (the “Company”), an agriculture products supplier in China and a logistics and supply chain services provider in the United States, today announced that it intends to offer in a public offering Class A ordinary shares of the Company.

The Company intends to use the net proceeds from this offering for general corporate and working capital needs. The Company’s Class A ordinary shares are trading on the Nasdaq Capital Market under the symbol “FAMI”. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the Offering.

Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.

The offering is being made pursuant to an effective shelf registration statement on Form F-3 (No 333-280348) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on June 27, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Farmmi, Inc.

Established in 1998, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is an agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi and other agricultural products. The Company also provides logistics and supply chain services in the United States. For further information about the Company, please visit: https://www.farmmi.com.

Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. Such offers may only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws.

Certain statements in this press release regarding the Company’s future growth prospects are forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: our ability to secure financing on favorable terms, customer order fulfillment, earnings volatility, exchange rate fluctuations, our ability to manage growth, the ability to generate revenue from business expansion and acquisitions, our ability to attract and retain qualified professionals, customer concentration, segment concentration, and other factors affecting the general economic conditions of the industry. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Farmmi may also make additional forward-looking statements from time to time in written or oral form, including in filings with the SEC and in reports to shareholders. Please note that all forward-looking statements are based on current assumptions believed to be reasonable as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

For more information, please contact: 
Farmmi, Inc.
Investor Relations
Tel: +86-0578-82612876
[email protected]

View original content:https://www.prnewswire.com/news-releases/farmmi-inc-announces-launch-of-proposed-public-offering-302812446.html

SOURCE Farmmi, Inc.